Plain-English translation of NCT07076823 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Colorectal Cancer research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing whether , a diabetes medication, works better when combined with tislelizumab (an immunotherapy drug) to treat advanced colorectal cancer. The study focuses on a specific type of colorectal cancer called MSI-H, which has shown promise with immune treatments. Researchers believe this medication may help the immune system fight cancer more effectively.
While current immunotherapy treatments help some people with this type of advanced colorectal cancer, many patients don't respond well enough or run into problems. This trial exists to see if adding this medication to the existing immunotherapy approach might improve results by helping the immune system work better against cancer cells.
You likely qualify if…
You likely don't qualify if…
You would receive an intravenous infusion of the immunotherapy drug tislelizumab every 3 weeks, and take the diabetes medication by mouth once daily before breakfast. The study starts with a lower dose of the medication, which may be increased if you tolerate it well. You will continue this treatment until your cancer progresses or side effects become too difficult to manage, with regular blood tests and imaging scans to monitor your response and safety.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
China